home / stock / scyx / scyx news

SCYX News and Press, SCYNEXIS Inc. From 11/13/23

Stock Information
Company Name: SCYNEXIS Inc.
Stock Symbol: SCYX
Market: NASDAQ
Website: scynexis.com
Menu
SCYX SCYX Quote SCYX Short SCYX News SCYX Articles SCYX Message Board
Get SCYX Alerts

News, Short Squeeze, Breakout and More Instantly...
SCYX - SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

IND enabling development activities for SCY-247, the next generation fungerp from SCYNEXIS’ proprietary antifungal platform, continue to advance Remediation strategies following the voluntary recall of BREXAFEMME ® and the MARIO study clinical hold are being evaluated ...
SCYX - Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against SCYNEXIS, Inc. (SCYX)

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired SCYNEXIS, Inc. (&#x...

SCYX - Expected US Company Earnings on Wednesday, November 8th, 2023

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

SCYX - Expected earnings - SCYNEXIS Inc.

SCYNEXIS Inc. (SCYX) is expected to report $0.29 for Q3 2023
SCYX - SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

JERSEY CITY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation funge...

SCYX - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

JERSEY CITY, N.J., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical data on its second generation funge...

SCYX - ALT, VYGR and SCYX are among after hour movers

2023-10-05 17:23:44 ET Gainers: nCino ( NASDAQ: NCNO ) +8% . TPI Composites ( TPIC ) +6% . SCYNEXIS ( SCYX ) +5% . Sutro Biopharma ( STRO ) +5% . Black Diamond Therapeutics ( BDTX ) +4% . Losers: SomaLogic ( SLGC ...
SCYX - Scynexis hit by FDA clinical hold on antifungal trials

2023-10-02 11:41:56 ET More on SCYNEXIS Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade) Scynexis recalling antifungal therapy on potential contamination Seeking Alpha’s Quant Rating on SCYNEXIS Historical ...

SCYX - Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Scynexis, Inc. (SCYX)

The law firm of Kirby McInerney LLP is investigating potential claims against Scynexis, Inc. (“Scynexis” or the “Company”) (NASDAQ: SCYX). The investigation concerns whether Scynexis and/or certain of its officers have violated the federal securities laws and/or en...

SCYX - SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

JERSEY CITY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. is conducting a voluntary nationwide recall of 2 lots of BREXAFEMME ® (ibrexafungerp tablets) to the consumer level in the US market due to potential cross contamination with a non-antibacterial ß-lactam drug subst...
Previous 10 Next 10